EP2086941B1 - Antibacterial quinoline derivatives - Google Patents

Antibacterial quinoline derivatives Download PDF

Info

Publication number
EP2086941B1
EP2086941B1 EP07847813A EP07847813A EP2086941B1 EP 2086941 B1 EP2086941 B1 EP 2086941B1 EP 07847813 A EP07847813 A EP 07847813A EP 07847813 A EP07847813 A EP 07847813A EP 2086941 B1 EP2086941 B1 EP 2086941B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
het
mono
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07847813A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2086941A1 (en
Inventor
Jérôme Emile Georges GUILLEMONT
Magali Madeleine Simone Motte
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to SI200730286T priority Critical patent/SI2086941T1/sl
Priority to EP07847813A priority patent/EP2086941B1/en
Priority to PL07847813T priority patent/PL2086941T3/pl
Publication of EP2086941A1 publication Critical patent/EP2086941A1/en
Application granted granted Critical
Publication of EP2086941B1 publication Critical patent/EP2086941B1/en
Priority to CY20101100708T priority patent/CY1110706T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Definitions

  • the present invention relates to novel substituted quinoline derivatives useful for the treatment of bacterial diseases, including but not limited to diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. leprae, M. avium and M. marinum, or pathogenic Staphylococci or Streptococci.
  • pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. leprae, M. avium and M. marinum, or pathogenic Staphylococci or Streptococci.
  • Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a serious and potentially fatal infection with a world-wide distribution.
  • TB tuberculosis
  • Estimates from the World Health Organization indicate that more than 8 million people contract TB each year, and 2 million people die from tuberculosis yearly. In the last decade, TB cases have grown 20% worldwide with the highest burden in the most impoverished communities. If these trends continue, TB incidence will increase by 41 % in the next twenty years. Fifty years since the introduction of an effective chemotherapy, TB remains after AIDS, the leading infectious cause of adult mortality in the world. Complicating the TB epidemic is the rising tide of multi-drug- resistant strains, and the deadly symbiosis with HIV. People who are HIV-positive and infected with TB are 30 times more likely to develop active TB than people who are HIV-negative and TB is responsible for the death of one out of every three people with HIV/AIDS worldwide
  • MDR-TB multi-drug- resistant strains
  • MDR-TB multi-drug- resistant strains
  • MDR-TB multi-drug- resistant strains
  • isoniazid and rifampin the most effective drugs of the four-drug standard, isoniazid and rifampin.
  • MDR-TB is lethal when untreated and cannot be adequately treated through the standard therapy, so treatment requires up to 2 years of "second-line" drugs. These drugs are often toxic, expensive and marginally effective.
  • infectious MDR-TB patients continue to spread the disease, producing new infections with MDR-TB strains.
  • drug resistant as used hereinbefore or hereinafter is a term well understood by the person skilled in microbiology.
  • a drug resistant Mycobacterium is a Mycobacterium which is no longer susceptible to at least one previously effective drug; which has developed the ability to withstand antibiotic attack by at least one previously effective drug.
  • a drug resistant strain may relay that ability to withstand to its progeny. Said resistance may be due to random genetic mutations in the bacterial cell that alters its sensitivity to a single drug or to different drugs.
  • MDR tuberculosis is a specific form of drug resistant tuberculosis due to a bacterium resistant to at least isoniazid and rifampicin (with or without resistance to other drugs), which are at present the two most powerful anti-TB drugs.
  • drug resistant includes multi drug resistant.
  • the dormant TB can get reactivated to cause disease by several factors like suppression of host immunity by use of immunosuppressive agents like antibodies against tumor necrosis factor ⁇ or interferon- ⁇ .
  • immunosuppressive agents like antibodies against tumor necrosis factor ⁇ or interferon- ⁇ .
  • the only prophylactic treatment available for latent TB is two- three months regimens of rifampicin, pyrazinamide.
  • the efficacy of the treatment regime is still not clear and furthermore the length of the treatments is an important constrain in resource-limited environments. Hence there is a drastic need to identify new drugs, which can act as chemoprophylatic agents for individuals harboring latent TB bacilli.
  • the tubercle bacilli enter healthy individuals by inhalation; they are phagocytosed by the alveolar macrophages of the lungs. This leads to potent immune response and formation of granulomas, which consist of macrophages infected with M. tuberculosis surrounded by T cells. After a period of 6-8 weeks the host immune response cause death of infected cells by necrosis and accumulation of caseous material with certain extracellular bacilli, surrounded by macrophages, epitheloid cells and layers of lymphoid tissue at the periphery.
  • Self-medication with antimicrobials is another major factor contributing to resistance.
  • Self-medicated antimicrobials may be unnecessary, are often inadequately dosed, or may not contain adequate amounts of active drug.
  • Patient compliance with recommended treatment is another major problem. Patients forget to take medication, interrupt their treatment when they begin to feel better, or may be unable to afford a full course, thereby creating an ideal environment for microbes to adapt rather than be killed.
  • W02004/011436 , WO2005/070924 , WO2005/070430 and WO2005/07542 disclose certain substituted quinoline derivatives having activity against Mycobacteria, in particular against Mycobacterium tuberculosis.
  • WO2005/117875 describes substituted quinoline derivatives having activity against resistant Mycobacterial strains.
  • WO2006/067048 describes substituted quinoline derivatives having activity against latent tuberculosis.
  • One particular compound of these substituted quinoline derivatives is described in Science (2005), 307, 223-227 and its mode of action is described in WO2006/035051 .
  • the purpose of the present invention is to provide novel compounds, in particular substituted quinoline derivatives, having the property of inhibiting bacterial growth especially of Streptococci, Staphylococci or mycobacteria and therefore useful for the treatment of bacterial diseases, particularly those diseases caused by pathogenic bacteria such as Streptococcus pneumonia, Staphylococcus aureus or Mycobacterium tuberculosis (including the latent disease and including drug resistant M . tuberculosis strains), M. bovis, M. leprae, M. avium and M. marinum.
  • the present invention relates to novel substituted quinoline derivatives according to formula (Ia) or (Ib): including any stereochemically isomeric form thereof, wherein
  • the compounds of formula (Ia) and (Ib) are interrelated in that e.g. a compound according to formula (Ib), with R 9 equal to oxo and R 8 equal to hydrogen, is the tautomeric equivalent of a compound according to formula (Ia) with R 2 equal to hydroxy (keto-enol tautomerism).
  • pyrrolyl comprises 1 H -pyrrolyl and 2 H -pyrrolyl.
  • aryl, aryl 1 or Het listed in the definitions of the substituents of the compounds of formula (Ia) or (Ib) may be attached to the remainder of the molecule of formula (Ia) or (Ib) through any ring carbon or heteroatom as appropriate, if not otherwise specified.
  • Het is imidazolyl, it may be 1-imidazolyl, 2-imidazolyl, 4-imidazolyl and the like.
  • the pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds according to formula (Ia) or formula (Ib) are able to form.
  • Said acid addition salts can be obtained by treating the base form of the compounds according to formula (Ia) or formula (Ib) with appropriate acids, for example inorganic acids, for example hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid; organic acids, for example acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicyclic acid
  • the compounds of formula (Ia) or (Ib) containing acidic protons may be converted into their therapeutically active non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
  • the pharmaceutically acceptable salts as mentioned hereinbefore or hereinafter are meant to also comprise the therapeutically active non-toxic metal or amine addition salt forms (base addition salt forms) which the compounds of formula (Ia) or (Ib) are able to form.
  • Appropriate base addition salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g.
  • primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisogropylamine, di- n -butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline, the benzathine, N -methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • said acid or base addition salt forms can be converted into the free forms by treatment with an appropriate base or acid.
  • pharmaceutically acceptable salt also comprises the quaternary ammonium salts (quaternary amines) which the compounds of formula (Ia) or (Ib) are able to form by reaction between a basic nitrogen of a compound of formula (Ia) or (Ib) and an appropriate quaternizing agent, such as, for example, an optionally substituted C 1-6 alkylhatide, arylC 1-6 alkylhalide, C 1-6 alkylcarbonylhalide, arylcarbonylhalide, HetC 1-6 alkylhalide or Hetcarbonylhalide, e.g. methyliodide or benzyliodide.
  • an appropriate quaternizing agent such as, for example, an optionally substituted C 1-6 alkylhatide, arylC 1-6 alkylhalide, C 1-6 alkylcarbonylhalide, arylcarbonylhalide, HetC 1-6 alkylhalide or Hetcarbonylhalide, e.g.
  • Het represents a monocyclic heterocycle selected from furanyl or thienyl; or a bicyclic heterocycle selected from benzofuranyl or benzothienyl; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, alkyl and aryl.
  • the quaternizing agent is C 1-6 alkylhalide.
  • Other reactants with good leaving groups may also be used, such as C 1-6 alkyl trifluoromethanesulfonates, C 1-6 alkyl methanesulfonates, and C 1-6 alkyl p-toluencsulfonatcs.
  • a quaternary amine has a positively charged nitrogen.
  • Pharmaceutically acceptable counterions include chloro, bromo, iodo, trifluoroacetate, acetate, triflate, sulfate, sulfonate.
  • the counterion is iodo.
  • the counterion of choice can be introduced using ion exchange resins.
  • solvate comprises the hydrates and solvent addition forms which the compounds of formula (Ia) or (Ib) are able to form, as well as the salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • stereochemically isomeric forms as used hereinbefore or hereinafter defines all the possible stereoisomeric forms which the compounds of formula (Ia) and (Ib), and their N -oxides, pharmaceutically acceptable salts, solvates or physiologically functional derivatives may possess.
  • chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms.
  • stereogenic centers may have the R- or S-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans- configuration.
  • an R or S descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center.
  • the configuration of the second stereogenic center is indicated using relative descriptors [ R *, R * ] or [ R *, S *], where R * is always specified as the reference center and [ R *, R *] indicates centers with the same chirality and [ R *, S *] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an S configuration and the second center is R , the stereo descriptor would be specified as S -[ R *, S *].
  • the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring umber is arbitrarily always in the " ⁇ " position of the mean plane determined by the ring system.
  • the position of the highest priority substituent on the other asymmetric carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated " ⁇ ", if it is on the same side of the mean plane determined by the ring system, or " ⁇ ", if it is on the other side of the mean plane determined by the ring system.
  • Compounds of either formula (Ia) and (Ib) and some of the intermediate compounds invariably have at least two stereogenic centers in their structure which may lead to at least 4 stereochemically different structures.
  • the compounds of either formula (Ia) and (Ib) may be synthesized in the form of mixtures, in particular racemic mixtures, of enantiomers which can be separated from one another following art-known resolution procedures.
  • the racemic compounds of either formula (Ia) and (Ib) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali.
  • An alternative manner of separating the enantiomeric forms of the compounds of either formula (Ia) and (Ib) involves liquid chromatography using a chiral stationary phase.
  • Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • tautomeric forms of the compounds of formula (Ia) or (Ib) are meant to comprise those compounds of formula (Ia) or (Ib) wherein e.g. an enol group is converted into a keto group (keto-enol tautomerism).
  • Tautomeric forms of the compounds of formula (Ia) and (Ib) or of intermediates of the present invention are intended to be embraced by the ambit of this invention.
  • N -oxide forms of the present compounds are meant to comprise the compounds of formula (Ia) or (Ib) wherein one or several tertiary nitrogen atoms are oxidized to the so-called N -oxide.
  • the compounds of formula (Ia) and (Ib) may be converted to the corresponding N -oxide forms following art-known procedures for converting a trivalent nitrogen into its N -oxide form.
  • Said N -oxidation reaction may generally be carried out by reacting the starting material of formula (Ia) or (Ib) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g.
  • organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • a compound according to the invention is inherently intended to comprise all isotopic combinations of its chemical elements.
  • a chemical element in particular when mentioned in relation to a compound according to formula (Ia) or (Ib), comprises all isotopes and isotopic mixtures of this element, either naturally occuring or synthetically produced, either with natural abundance or in an isotopically enriched form.
  • a compound according to the invention therefore inherently comprises a compound with one or more isotopes of one or more element, and mixtures thereof, including a radioactive compound, also called radiolabelled compound, wherein one or more nonradioactive atoms has been replaced by one of its radioactive isotopes.
  • radiolabelled compound is meant any compound according to formula (Ia) or (Ib), a pharmaceutically acceptable salt thereof or an N -oxide form thereof or a solvate thereof, which contains at least one radioactive atom.
  • a compound can be labelled with positron or with gamma emitting radioactive isotopes.
  • the 3 H-atom or the 125 I-atom is the atom of choice to be replaced.
  • the most commonly used positron emitting (PET) radioactive isotopes are 11 C, 18 F, 15 O and 13 N, all of which are accelerator produced and have half-lives of 20, 100, 2 and 10 minutes respectively. Since the half-lives of these radioactive isotopes are so short, it is only feasible to use them at institutions which have an accelerator on site for their production, thus limiting their use. The most widely used of these are 18 F, 99m Tc, 201 Tl and 123 I.
  • the radioactive atom is selected from the group of hydrogen, carbon, nitrogen, sulfur, oxygen and halogen.
  • the radioactive atom is selected from the group of hydrogen, carbon and halogen.
  • the radioactive isotope is selected from the group of 3 H, 11 C, 18 F, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br and 82 Br.
  • the radioactive isotope is selected from the group of 3 H, "C and 8 F.
  • alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with cyano, hydroxy, C 1-6 alkyloxy or oxo.
  • alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with hydroxyl or C 1-6 alkyloxy.
  • alkyl is methyl, ethyl or cyclohexylmethyl, more preferably methyl or ethyl.
  • alkyl in all definitions used hereinbefore or hereinafter is C 1-6 alkyl which represents a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms such as for example methyl, ethyl, propyl, 2-methyl-ethyl, pentyl, hexyl and the like.
  • a preferred subgroup of C 1-6 alkyl is C 1-4 alkyl which represents a straight or branched saturated hydrocarbon radical having from 1 to 4 carbon atoms such as for example methyl, ethyl, propyl, 2-methyl-ethyl and the like.
  • C 2-6 alkenyl is a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms containing a double bond such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like
  • C 2-6 alkynyl is a straight or branched hydrocarbon radical having from 2 to 6 carbon atoms containing a triple bond such as ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like
  • C 3-6 cycloalkyl is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms and is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein one or more carbon atoms are substituted with one or more halo atoms.
  • halo is bromo, fluoro or chloro; in particular chloro or bromo.
  • haloalkyl is polyhaloC 1-6 alkyl which is defined as mono- or polyhalosubstituted C 1-6 alkyl, for example, methyl with one or more fluoro atoms, for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl and the like.
  • fluoro atoms for example, difluoromethyl or trifluoromethyl, 1,1-difluoro-ethyl and the like.
  • halo atom is attached to an alkyl or C 1-6 alkyl group within the definition of haloalkyl or polyhaloC 1-6 alkyl, they may be the same or different.
  • a first interesting embodiment relates to a compound of formula (Ia) or (Ib) including any stereochemically isomeric form thereof, wherein
  • a second interesting embodiment relates to a compound of formula (Ia) or (Ib) wherein
  • a third interesting embodiment relates to a compound of formula (Ia) or (Ib) wherein
  • a fourth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 1 is hydrogen, cyano, halo, alkyl, haloalkyl, hydroxy, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, arylalkyl, di(aryl)alkyl, aryl, or Het; in particular R 1 is hydrogen, halo, aryl, Het, alkyl or alkyloxy; more in particular R 1 is halo. Most preferably, R 1 is bromo.
  • a fifth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein p is equal to 1.
  • a sixth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 2 is hydrogen, alkyloxy or alkylthio, in particular hydrogen, C 1-6 alkyloxy or C 1-6 alkylthio. More in particular, R 2 is C 1-6 alkyloxy, preferably methyloxy.
  • a seventh interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 3 is C 1-6 alkyl, C 3 - 6 cycloalkyl, arylC 1-6 alkyl, aryl, Het, Het-C 1-6 alkyl; in particular aryl or arylC 1-6 alkyl; more in particular optionally substituted phenyl; even more in particular phenyl. Or R 3 is aryl-O-C 1-6 alkyl, arylC 1-6 alkyl-O-C 1-6 alkyl, aryl-aryl, Het-O-C 1-6 alkyl,
  • HetC 1-6 alkyl-O-C 1-6 alkyl, or or R 3 is aryl-O-C 1-6 alkyl, arylC 1-6 alkyl-O-C 1-6 alkyl, Het-O-C 1-6 alkyl,
  • An eighth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein q is equal to 1 or 2. More preferably, q is equal to 1.
  • a ninth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein Z is S.
  • a tenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein Z is NR 10 .
  • An eleventh interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 4 and R 5 each independently represent hydrogen or C 1-6 alkyl, in particular C 1-6 alkyl, more in particular methyl or ethyl. Preferably R 4 and R 5 are methyl.
  • a twelfth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 4 and R 5 together with the nitrogen atom to which they are attached form a radical selected from the group consisting of piperidino, piperazino, morpholino, imidazolyl, triazolyl, each of said rings optionally substituted with C 1-6 alkyl; more in particular piperidino or piperazino, each of said rings optionally substituted with C 1-4 alkyl; even more in particular piperidino or piperazino optionally substituted with C 1-4 alkyl.
  • a thirteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 6 is phenyl optionally substituted with halo, cyano or C 1-6 alkyloxy; in particular phenyl optionally substituted with halo; more in particular phenyl.
  • a fourteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 7 is hydrogen.
  • a fifteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein the compound is a compound of formula (Ia).
  • a sixteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein the compound is a compound of formula (Ib) and wherein R 8 is hydrogen and R 9 is oxo.
  • a seventeenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein the compound is a compound of formula (Ib), in particular wherein R 8 is alkyl, more preferable C 1-6 alkyl, e.g. methyl.
  • An eighteenth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 10 is C 1-6 alkyl or benzyl.
  • a nineteenth interesting embodiment is a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein aryl is naphthyl or phenyl, more preferably phenyl, each optionally substituted with one or two substituents selected from halo, for example chloro; cyano; alkyl for example methyl; or alkyloxy, for example methyloxy.
  • aryl is naphthyl or phenyl, more preferably phenyl, each optionally substituted with one or two substituents selected from halo, for example chloro; cyano; alkyl for example methyl; or alkyloxy, for example methyloxy.
  • a twentieth interesting embodiment relates to a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein R 1 is placed in position 6 of the quinoline ring.
  • the quinoline ring of the compounds of formula (Ia) or (Ib) is numbered as follows :
  • a twenty first interesting embodiment is the use of a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment for the manufacture of a medicament for the treatment of a bacterial infection with a gram-positive and/or a gram-negative bacterium, preferably a bacterial infection with a gram-positive bacterium.
  • a twenty second interesting embodiment is the use of a compound of formula (Ia) or (Ib) or any subgroup thereof as mentioned hereinbefore as interesting embodiment for the manufacture of a medicament for the treatment of a bacterial infection
  • the compound of formula (Ia) or (Ib) has a IC 90 ⁇ 15 ⁇ l/ml against at least one bacterium, in particular a gram-positive bacterium; preferably a IC 90 ⁇ 10 ⁇ l/ml; more preferably a IC 90 ⁇ 5 ⁇ l/ml; the IC 90 value being determined as described hereinafter.
  • a twenty third interesting embodiment relates to a compound of formula (Ia) or any subgroup thereof as mentioned hereinbefore as interesting embodiment wherein one or more, preferably all, of the following definitions apply :
  • alkyl represents C 1-6 alkyl, more preferably C 1-4 alkyl, and the term haloalkyl represents polyhaloC 1-6 alkyl.
  • the compound of formula (Ia) or (Ib) is a particular mixture of enantiomers (hereinafter indicated as a particular A or B diastereoisomer) and hence is substantially free of the other diastereoisomer(s)).
  • the compound of formula (Ia) or (Ib) has two chiral centers, this means that the compound is a mixture, in particular a racemic mixture, of the (R,S) and (S,R) enantiomers or a mixture, in particular a racemic mixture, of the (R,R) and (S,S) enantiomer.
  • the mixtures, in particular the racemic mixtures, of 2 enantiomers are indicated as diastereoisomer A or B.
  • the racemic mixture is indicated as A or B depends on whether it is first isolated in the synthesis protocol (i.e. A) or second (i.e. B).
  • the compound of formula (Ia) or (Ib) is a particular enantiomer (substantially free of the other enantiomers).
  • the compound of formula (Ia) or (Ib) has two chiral centers this means that the compound is the (R,S), (S,R), (R,R) or (S,S) enantiomer.
  • said particular enantiomers are indicated as A1, A2, B1 or B2. Whether the enantiomer is indicated as A1, A2, B1 or B2 depends on whether it is isolated first or second (1 or 2) in the synthesis protocol and whether it is separated from the A (A1, A2) or B (B1, B2) diastereoisomer.
  • the compounds according to the invention have surprisingly been shown to be suitable for the treatment of a bacterial infection including a mycobacterial infection, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis (including the latent and drug resistant form thereof), M. bovis, M. avium, M. leprae and M. marinum.
  • the present invention thus also relates to compounds of formula (Ia) or (Ib) as defined hereinabove, the pharmaceutically acceptable salts thereof or the N -oxide forms thereof or the solvates thereof, for use as a medicine, in particular for use as a medicine for the treatment of a bacterial infection including a mycobacterial infection.
  • the present invention also relates to the use of a compound of formula (Ia) or (Ib), the pharmaceutically acceptable salts thereof or the N -oxide forms thereof or the solvates thereof, as well as any of the pharmaceutical compositions thereof as described hereinafter for the manufacture of a medicament for the treatment of a bacterial infection including a mycobacterial infection.
  • the invention discloses a method of treating a patient suffering from, or at risk of, a bacterial infection, including a mycobacterial infection, which comprises administering to the patient a therapeutically effective amount of a compound or pharmaceutical composition according to the invention.
  • the compounds according to the invention are also active against other bacteria.
  • bacterial pathogens may be classified as either gram-positive or gram-negative pathogens.
  • Antibiotic compounds with activity against both gram-positive and gram-negative pathogens are generally regarded as having a broad spectrum of activity.
  • the compounds of the present invention are regarded as active against gram-positive and/or gram-negative bacterial pathogens, in particular against gram-positive bacterial pathogens.
  • the present compounds are active against at least one gram-positive bacterium, preferably against several gram-positive bacteria, more preferably against one or more gram-positive bacteria and/or one or more gram-negative bacteria.
  • the present compounds have bactericidal or bacteriostatic activity.
  • Examples of gram-positive and gram-negative aerobic and anaerobic bacteria include Staphylococci, for example S. aureus; Enterococci, for example E.faecalis; Streptococci, for example S. pneumoniae, S. mutans, S. pyogens; Bacilli, for example Bacillus subtilis; Listeria, for example Listeria monocytogenes; Haemophilus, for example H. influenza; Moraxella, for example M. catarrhalis; Pseudomonas, for example Pseudomonas aeruginosa; and Escherichia, for example E. coli.
  • Staphylococci for example S. aureus
  • Enterococci for example E.faecalis
  • Streptococci for example S. pneumoniae, S. mutans, S. pyogens
  • Bacilli for example Bacillus subtilis
  • Listeria for example Listeria monocytogenes
  • Gram-positive pathogens for example Staphylococci, Enterococci and Streptococci are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from for example a hospital environment once established.
  • Examples of such strains are methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiple resistant Enterococcus faecium.
  • the compounds of the present invention also show activity against resistant bacterial strains.
  • the compounds of the present invention are especially active against Streptococcus pneumoniae and Staphylococcus aureus, including resistant Staphylococcus aureus such as for example methicillin resistant Staphylococcus aureus (MRSA).
  • MRSA methicillin resistant Staphylococcus aureus
  • the present invention also relates to the use of a compound of formula (Ia) or (Ib), the pharmaceutically acceptable salts thereof or the N -oxide forms thereof or the solvates thereof, as well as any of the pharmaceutical compositions thereof as described hereinafter for the manufacture of a medicament for the treatment of a bacterial infection including an infection caused by Staphylococci and/or Streptococci.
  • the invention discloses a method of treating a patient suffering from, or at risk of, a bacterial infection, including an infection caused by Staphylococci and/or Streptococci, which comprises administering to the patient a therapeutically effective amount of a compound or pharmaceutical composition according to the invention.
  • the activity of the present compounds lies in inhibition of the F1F0 ATP synthase, in particular the inhibition of the F0 complex of the F1F0 ATP synthase, more in particular the inhibition of subunit c of the F0 complex of the F1F0 ATP synthase, leading to killing of the bacteria by depletion of the cellular ATP levels of the bacteria. Therefore, in particular, the compounds of the present invention are active on those bacteria of which the viability depends on proper functioning of F1F0 ATP synthase.
  • Bacterial infections which may be treated by the present compounds include, for example, central nervous system infections, external ear infections, infections of the middle ear, such as acute otitis media, infections of the cranial sinuses, eye infections, infections of the oral cavity, such as infections of the teeth, gums and mucosa, upper respiratory tract infections, lower respiratory tract infections, genitourinary infections, gastrointestinal infections, gynaecological infections, septicemia, bone and joint infections, skin and skin structure infections, bacterial endocarditis, bums, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in immunosuppressed patients, such as patients receiving cancer chemotherapy, or organ transplant patients.
  • the compounds can treat a bacterial infection it is meant that the compounds can treat an infection with one or more bacterial strains.
  • the invention also relates to a composition
  • a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to the invention.
  • the compounds according to the invention may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by weight, even more preferably from 0.1 to 50 % by weight of the active ingredient(s), and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 % by weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.
  • the pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.
  • a lubricant for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.
  • Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • the daily dosage of the compound according to the invention will, of course, vary with the compound employed, the mode of administration, the treatment desired and the mycobacterial disease indicated. However, in general, satisfactory results will be obtained when the compound according to the invention is administered at a daily dosage not exceeding 1 gram, e.g. in the range from 10 to 50 mg/kg body weight.
  • the present compounds may be combined with other antibacterial agents in order to effectively combat bacterial infections.
  • the present invention also relates to a combination of (a) a compound according to the invention, and (b) one or more other antibacterial agents.
  • the present invention also relates to a combination of (a) a compound according to the invention, and (b) one or more other antibacterial agents, for use as a medicine.
  • the present invention also relates to the use of a combination or pharmaceutical composition as defined directly above for the treatment of a bacterial infection.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of (a) a compound according to the invention, and (b) one or more other antibacterial agents, is also comprised by the present invention.
  • the weight ratio of (a) the compound according to the invention and (b) the other antibacterial agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other antibacterial agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. A particular weight ratio for the present compound of formula (Ia) or (Ib) and another antibacterial agent may range from 1/10 to 10/1, more in particular from 1/5 to 5/1, even more in particular from 1/3 to 3/1.
  • the compounds according to the invention and the one or more other antibacterial agents may be combined in a single preparation or they may be formulated in separate preparations so that they can be administered simultaneously, separately or sequentially.
  • the present invention also relates to a product containing (a) a compound according to the invention, and (b) one or more other antibacterial agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of a bacterial infection.
  • the other antibacterial agents which may be combined with the compounds of formula (Ia) or (Ib) are for example antibacterial agents known in the art.
  • the other antibacterial agents comprise antibiotics of the ⁇ -lactam group such as natural penicillins, semisynthetic penicillins, natural cephalosporins, semisynthetic cephalosporins, cephamycins, 1-oxacephems, clavulanic acids, penems, carbapenems, nocardicins, monobactams; tetracyclines, anhydrotetracyclines, anthracyclines; aminoglycosides; nucleosides such as N -nucleosides, C-nucleosides, carbocyclic nucleosides, blasticidin S; macrolides such as 12-membered ring macrolides, 14-membered ring macrolides, 16-membered ring macrolides; ansamycins; peptides such as bleo
  • antibiotics which may be combined with the present compounds of formula (Ia) or (Ib) are for example benzylpenicillin (potassium, procaine, benzathine), phenoxymethylpenicillin (potassium), phenethicillin potassium, propicillin, carbenicillin (disodium, phenyl sodium, indanyl sodium), sulbenicillin, ticarcillin disodium, methicillin sodium, oxacillin sodium, cloxacillin sodium, dicloxacillin, flucloxacillin, ampicillin, mezlocillin, piperacillin sodium, amoxicillin, ciclacillin, hectacillin, sulbactam sodium, talampicillin hydrochloride, bacampicillin hydrochloride, pivmecillinam, cephalexin, cefaclor, cephaloglycin, cefadroxil, cephradine, cefroxadine, cephapirin sodium, cephalothin sodium, ce
  • isoniazid pyrazinamide
  • the compounds according to the invention can generally be prepared by a succession of steps, each of which is known to the skilled person.
  • the compounds of formula (Ia) or (Ib) can be prepared by reacting an intermediate of formula (IIa) or (IIb) with an intermediate of formula (III) according to the following reaction scheme (1) : using nBuLi in a mixture of a suitable base, such as for example diisopropyl amine, and a suitable solvent, such as for example tetrahydrofuran, wherein all variables are defined as in formula (Ia) or (Ib). Stirring may enhance the rate of the reaction.
  • the reaction may conveniently be carried out at a temperature ranging between -20 and -70 °C.
  • the compounds of formula (Ia) or (Ib) may further be prepared by converting compounds of formula (Ia) or (Ib) into each other according to art-known group transformation reactions.
  • the compounds of formula (Ia) or (Ib) may be converted to the corresponding N -oxide forms following art-known procedures for converting a trivalent nitrogen into its N -oxide form.
  • Said N -oxidation reaction may generally be carried out by reacting the starting material of formula (Ia) or (Ib) with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g.
  • organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • compounds of formula (Ia) or (Ib) in which R 1 is halo, for example bromo may be converted into a compound of formula (Ia) or (Ib) in which R 1 is alkyl, for example methyl, by treatment with an appropriate alkylating agent such as CH 3 B(OH) 2 or (CH 3 ) 4 Sn in the presence of a suitable catalyst, such as for example Pd(PPh 3 ) 4 , in a suitable solvent such as for example toluene or 1,2-dimethoxyethane (DME).
  • an appropriate alkylating agent such as CH 3 B(OH) 2 or (CH 3 ) 4 Sn
  • a suitable catalyst such as for example Pd(PPh 3 ) 4
  • a suitable solvent such as for example toluene or 1,2-dimethoxyethane (DME).
  • Compounds of formula (Ia) or (Ib) wherein R 1 represents C 2-6 alkenyl can be prepared by reacting a compound of formula (Ia) or (Ib) wherein R 1 is halo, e.g. bromo and the like, with tributyl(C 2-6 alkenyl)tin, such as for example tributyl(vinyl)tin, in the presence of a suitable catalyst, such as for example Pd(PPh 3 ) 4 , in the presence of a suitable solvent, such as for example N , N -dimethylformamide. This reaction is preferably performed at elevated temperature.
  • R 1 represents R 5a R 4a N-
  • R 1 represents R 5a R 4a N-
  • R 1 is halo, e.g. bromo and the like
  • a suitable catalyst such as for example tris(dibenzylideneacetone)palladium
  • a suitable ligand such as for example 2-(di-t-butylphosphino)biphenyl
  • a suitable base such as for example sodium t-butoxide
  • a suitable solvent such as for example toluene.
  • Compounds of formula (Ia) or (Ib) wherein R 1 represents -CH 2 -NH 2 can be prepared from a compound of formula (Ia) or (Ib) wherein R 1 is formyl, by reduction in the presence of H 2 , a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example NH 3 /alcohol, e.g. NH 3 /methanol.
  • a suitable catalyst such as for example palladium on charcoal
  • a suitable solvent such as for example NH 3 /alcohol, e.g. NH 3 /methanol.
  • Compounds of formula (Ia) or (Ib) wherein R 1 represents R 5a R 4a N-CH 2 - can be prepared by reacting a compound of formula (Ia) or (Ib) wherein R 1 is formyl, with a suitable reagent of formula R 5a R 4a N-H in the presence of a suitable reducing agent, such as for example BH 3 CN, a suitable solvent, such as for example acetonitrile and tetrahydrofuran, and a suitable acid, such as for example acetic acid.
  • a suitable reducing agent such as for example BH 3 CN
  • a suitable solvent such as for example acetonitrile and tetrahydrofuran
  • a suitable acid such as for example acetic acid.
  • Compounds of formula (Ia) or (Ib) wherein R 1 represents amino can be prepared by reacting a compound of formula (Ia) or (Ib) wherein R 1 is carboxyl, with a suitable azide, such as for example diphenylphosphorylazide (DPPA), and a suitable base, such as for example triethylamine, in a suitable solvent, such as for example toluene.
  • a suitable azide such as for example diphenylphosphorylazide (DPPA)
  • a suitable base such as for example triethylamine
  • a suitable amine such as for example hydroxybenzotriazole
  • a suitable activating reagent such as for example 1,1'-carbonyldiimidazole or N , N '-dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
  • a suitable base such as for example triethylamine
  • a suitable solvent such as for example tetrahydrofuran and methylenechloride.
  • Compounds of formula (Ia) or (Ib) wherein R 1 represents arylcarbonyl can be prepared by reacting in a first step (a) a compound of formula (Ia) or (Ib) wherein R 1 is halo, e.g. bromo and the like, with a suitable arylaldehyde in the presence of nBuLi and a suitable solvent, such as for example tetrahydrofuran. This reaction is preferably performed at low temperature such as for example -70°C.
  • a suitable oxidans such as for example manganese oxide
  • a suitable solvent such as for example methylene chloride.
  • Compounds of formula (Ia) or (Ib) wherein R 4 and R 5 represent an unsubstituted ring moiety can be prepared from the corresponding compound wherein the ring moiety is substituted with arylalkyl, by reaction with ammonium formate in the presence of a suitable catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for example an alcohol, e.g. methanol.
  • a suitable catalyst such as for example palladium on charcoal
  • a suitable solvent such as for example an alcohol, e.g. methanol.
  • a compound of formula (Ia) wherein R 2 represents methoxy can be converted into the corresponding compound of formula (Ib) wherein R 8 is hydrogen and R 9 is oxo, by hydrolysis in the presence of a suitable acid, such as for example hydrochloric acid, and a suitable solvent, such as for example dioxane.
  • a suitable acid such as for example hydrochloric acid
  • a suitable solvent such as for example dioxane
  • Compounds of formula (Ia) or (Ib) wherein R 4 and R 5 are taken together with the nitrogen to which they are attached to form 1,1-dioxide-thiomorpholinyl, can be prepared from the corresponding thiomorpholine derivative by reaction with an appropriate organic or inorganic peroxide.
  • Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g.
  • 3-chlorobenzenecarboperoxoic acid peroxoalkanoic acids, e.g. peroxoacetic acid, alkylhydroperoxides, e.g. tert.butyl hydro-peroxide.
  • Suitable solvents are, for example, water, lower alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g. dichloromethane, and mixtures of such solvents.
  • Compounds of formula (Ia) or (Ib) can also be converted into a quaternary amine by reaction with a suitable quatemizing agent, such as, for example, an optionally substituted C 1-6 alkylhalide, arylC 1-6 alkylhalide, C 1-6 alkylcarbonylhalide, arylcarbonylhalide, Het 1 C 1-6 alkylhalide or Het 1 carbonylhalide, e.g.
  • a suitable quatemizing agent such as, for example, an optionally substituted C 1-6 alkylhalide, arylC 1-6 alkylhalide, C 1-6 alkylcarbonylhalide, arylcarbonylhalide, Het 1 C 1-6 alkylhalide or Het 1 carbonylhalide, e.g.
  • methyliodide or benzyliodide in the presence of a suitable solvent, such as for example acetone wherein Het 1 represents furanyl or thienyl; or a bicyclic heterocycle selected from benzofuranyl or benzothienyl; each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, C 1-6 alkyl and aryl.
  • a suitable solvent such as for example acetone wherein Het 1 represents furanyl or thienyl
  • a bicyclic heterocycle selected from benzofuranyl or benzothienyl
  • each monocyclic and bicyclic heterocycle may optionally be substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, C 1-6 alkyl and aryl.
  • Said quaternary amines are represented by the below formula wherein R 12 represents C 1-6 alkyl, C 1 - 6 alkylcarbonyl, arylC 1-6 alkyl, arylcarbonyl, Het 1 C 1-6 alkyl or Het 1 carbonyl and wherein A - represents a pharmaceutically acceptable counterion, such as for example iodide.
  • reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art, such as extraction, crystallization and chromatography. It is further evident that reaction products that exist in more than one enantiomeric form, may be isolated from their mixture by known techniques, in particular preparative chromatography, such as preparative HPLC, chiral chromatography. Individual diastereoisomers or individual enantiomers can also be obtained by Supercritical Fluid Chromatography (SCF).
  • SCF Supercritical Fluid Chromatography
  • reaction scheme (2) comprises step (a) in which an appropriately substituted aniline is reacted with an appropriate acylchloride such as for example 3-phenylpropionyl chloride, 3-fluorobenzenepropionyl chloride or p-chlorobenzenepropionyl chloride, in the presence of a suitable base, such as triethylamine, and a suitable reaction-inert solvent, such as methylene chloride or ethylene dichloride.
  • acylchloride such as for example 3-phenylpropionyl chloride, 3-fluorobenzenepropionyl chloride or p-chlorobenzenepropionyl chloride
  • a suitable base such as triethylamine
  • reaction-inert solvent such as methylene chloride or ethylene dichloride.
  • the reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature.
  • adduct obtained in step (a) is reacted with phosphoryl chloride (POCl 3 ) in the presence of N , N -dimethylformamide (Vilsmeier-Haack formylation followed by cyclization).
  • the reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature.
  • a specific R 2 -group, wherein R 2 is for example a C 1-6 alkyloxy radical is introduced by reacting the intermediate compound obtained in step (b) with O-C 1-6 alkyl in the presence of a suitable solvent, such as for example HO-C 1-6 alkyl.
  • a suitable solvent such as for example an alcohol, e.g. ethanol, or an alcohol/water mixture
  • a suitable base such as for example KOH
  • the intermediate obtained in step (b) can also be converted into an intermediate wherein R 2 is -N(R 2a )(alkyl) wherein R 2a is hydrogen or alkyl, by reaction with a suitable salt of NH(R 2a )(alkyl) in the presence of a suitable base, such as for example potassium carbonate, and a suitable solvent, such as for example acetonitrile (step (c-3)).
  • a suitable base such as for example potassium carbonate
  • a suitable solvent such as for example acetonitrile
  • the intermediate obtained in step (b) can also be converted into an intermediate wherein R 2 is C 1-6 alkyloxyC 1-6 alkyloxy optionally substituted with C 1-6 alkyloxy, said R 2 being represented by R 2b , by reaction with C 1-6 alkyloxC 1-6 yalkylOH optionally substituted with C 1-6 alkyloxy, in the presence of NaH and a suitable solvent, such as for example tetrahydrofuran (step (c-4)).
  • a suitable solvent such as for example tetrahydrofuran
  • Intermediates of formula (IIa) wherein R 2 and R 7 represent hydrogen may be prepared according to the following reaction scheme (3), wherein in a first step (a) a substituted indole-2,3-dione is reacted with an optionally substituted 3-phenylpropionaldehyde in the presence of a suitable base such as sodium hydroxide (Pfitzinger reaction), after which the carboxylic acid compound is decarboxylated in a next step (b) at high temperature in the presence of a suitable reaction-inert solvent such as diphenylether.
  • a suitable base such as sodium hydroxide
  • the reaction may conveniently be carried out at a temperature ranging between -20 and -70°C.
  • step (b) the product obtained in step (a) is converted in aan intermediate of formula (IIa-6) by reaction with a suitable acid, such as for example trifluoroacetic acid, and triisopropylsilane, in the presence of a suitable solvent, such as for example methylene chloride.
  • a suitable acid such as for example trifluoroacetic acid, and triisopropylsilane
  • Reaction scheme (4) comprises step (a) in which the quinoline moiety is converted in the quinolinone moiety by reaction with a suitable acid, such as for example hydrochloric acid.
  • a R 8 substituent is introduced by reacting the intermediate obtained in step (a) with a suitable alkylating agent, such as for example alkyliodide, e.g. methyliodide, in the presence of a suitable base, such as for example NaOH or benzyltriethylammonium chloride, a suitable solvent, such as for example tetrahydrofuran.
  • a suitable alkylating agent such as for example alkyliodide, e.g. methyliodide
  • a suitable base such as for example NaOH or benzyltriethylammonium chloride
  • a suitable solvent such as for example tetrahydrofuran.
  • Reaction scheme (5) comprises step (a) in which the intermediate is reacted with NH 2 -CH 2 -CH(OCH 3 ) 2 .
  • step (b) the fused imidazolyl moiety is formed by reaction with acetic acid in the presence of a suitable solvent, such as for example xylene.
  • intermediates of formula (III) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art.
  • intermediates of formula (III) may be prepared according to the following reaction scheme (6):
  • a suitable base such as for example N , N -diethylisopropylamine
  • a suitable solvent such as
  • a suitable leaving group such as for example halo, e.g. chloro and the like, such as for example 3-chloro-1-propanethiol
  • an amino group (-NR 4 R 5 ) is introduced by reacting the intermediate compound obtained in step (a) with a primary or secondary amine HNR 4 R 5 , such as for example piperidine, N , N -diethylamine, 1-methylpiperazine, in the presence of a suitable solvent, such as for example acetonitrile, and a suitable base, such as for example K 2 CO 3 .
  • a primary or secondary amine HNR 4 R 5 such as for example piperidine, N , N -diethylamine, 1-methylpiperazine
  • Intermediates of formula (III) wherein R 3 represents a halo substituted phenyl may be converted into an intermediate of formula (III) wherein R 3 represents phenyl substituted with aryl, by reaction with arylboronic acid in the presence of a suitable base, such as for example potassium phosphate, a suitable catalyst, such as for example palladium acetate, and a suitable ligand, such as for example 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, in an appropriate solvent, such as for example toluene.
  • a suitable base such as for example potassium phosphate
  • a suitable catalyst such as for example palladium acetate
  • a suitable ligand such as for example 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
  • Intermediates of formula (III) wherein R 3 represents a halo substituted phenyl may also be converted into an intermediate of formula (III) wherein R 3 represents phenyl substituted with C 2-6 alkenyl optionally substituted with phenyl, by reaction with an appropriate C 2-6 alkene, such as for example styrene, in the presence of a suitable base, such as for example triethylamine, a suitable catalyst, such as for example palladium acetate, and a suitable ligand, such as for example tri-o-tolylphosphine, in an appropriate solvent, such as for example DMF.
  • a suitable base such as for example triethylamine
  • a suitable catalyst such as for example palladium acetate
  • a suitable ligand such as for example tri-o-tolylphosphine
  • the suitable amine HNR 4 R 5 represents substituted 2,5-diazabicyclo[2.2.1]heptyl, said amine can be prepared according to the following reaction scheme (8):
  • Reaction scheme (8) comprises the step of reacting an appropriately protected 2,5-diazabicyclo[2.2.1]heptyl wherein P represents for instance tert -butyloxycarbonyl, with an appropriate reagens of formula W-R' wherein W represents a suitable leaving group, such as for example halo, e.g.
  • R' represents the substituent to be introduced, in the presence of a suitable base, such as for example K 2 CO 3 , NaHCO 3 or triethylamine, a suitable phase transfer reagent; such as for example tetra-n-butylammonium chloride, a suitable solvent, such as for example acetonitrile, and optionally KI to increase the speed of the reaction.
  • a suitable base such as for example K 2 CO 3 , NaHCO 3 or triethylamine
  • a suitable phase transfer reagent such as for example tetra-n-butylammonium chloride
  • a suitable solvent such as for example acetonitrile
  • optionally KI to increase the speed of the reaction.
  • the protective group is removed by reaction with a suitable acid, such as for example trifluoroacetic acid in the presence of a suitable solvent, such as for example methylene chloride.
  • the intermediates of formula (IV) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art.
  • the absolute stereochemical configuration of the stereogenic carbon atom(s) therein or the configuration at the double bond was not experimentally determined.
  • the stereochemically isomeric form which was first isolated is designated as "A” and the second as "B”, without further reference to the actual stereochemical configuration.
  • said "A” and "B” isomeric forms can be unambiguously characterized by a person skilled in the art, using art-known methods such as, for example, NMR. It is considered to be within the knowledge of the skilled person to recognize the most appropriate method to determine the actual stereochemical configuration.
  • a final compound or an intermediate indicated as a particular diastereoisomer or enantiomer
  • the latter may inherit the indication for diastereoisomer (A or B) or enantiomer (A1, A2, B1, B2) from the former.
  • THF tetrahydrofuran
  • Intermediate 8 was prepared according to the procedure for intermediate 1 as described in A1.a, starting from 2-chloroacetophenone and N,N,N'- trimethylethylenediamine (CAS [142-25-6]). Yield: 57 %.
  • Intermediate 9 was prepared according to the procedure for intermediate 1 as described in A1.a, starting from 2-chloroacetophenone and 2-dimethylaminoethanethiol hydrochloride (CAS [13242-44-9]). Yield: 98 %.
  • Intermediate 2 was prepared according to the procedure for intermediate 1 as described in A1.a, starting from 2-chloroacetophenone and 3-chloro-1-propanethiol (CAS [17481-19-5]). Yield: 99 %.
  • Intermediate 5 was prepared according to the procedure for intermediate 3 as described in A2.b, starting from intermediate 2 and dimethylamine hydrochloride (CAS [506-59-2]). Yield: 82 %.
  • Intermediate 6 was prepared according to the procedure for intermediate 3 as described in A2.b, starting from intermediate 2 and 1-methylpiperazine (CAS [103-01-3]). Yield: 26 %.
  • nBuLi 1.6M in hexane (8.6 ml, 0.0138mol) was added slowly at -20°C under N 2 flow to a solution of diisopropylamine (1.9 ml, 0.0138 mol) in THF (25 ml). The mixture was stirred at -20°C for 20 minutes, and then cooled at -70°C. A solution of 6-bromo-2-methoxy-3-(phenylmethyl)-quinoline (3.7 g, 0.0115 mol) (intermediate compound 3 (Ex. A3) of WO2004/011436 ) in THF (38 ml) was added slowly. The mixture was stirred at -70°C for 90 minutes.
  • Tables 1 and 2 list compounds of formula (Ia) according to the present invention.
  • the HPLC measurement was performed using an Alliance HT 2795 (Waters) system comprising a quaternary pump with degasser, an autosampler, a diode-array detector (DAD) and a column as specified in the respective methods below, the column is hold at a temperature of 30°C. Flow from the column was split to a MS spectrometer.
  • the MS detector was configured with an electrospray ionization source.
  • the capillary needle voltage was 3 kV and the source temperature was maintained at 100°C on the LCT (Time of Flight ZsprayTM mass spectrometer from Waters - for method 1), and 3.15 k V at 110°C on the ZQTM (simple quadrupole ZsprayTM mass spectrometer from Waters - for method 2). Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
  • Method 1 In addition to the general procedure: Reversed phase HPLC was carried out on a Kromasil C18 column (5 ⁇ m, 4.6 x 150 mm) with a flow rate of 1.0 ml/min. Three mobile phases (mobile phase A: 100 % 7 mM ammonium acetate; mobile phase B: 100 % acetonitrile; mobile phase C: 0.2 % formic acid + 99.8 % ultra-pure Water) were employed to run a gradient condition from 30 % A , 40 % B and 30 % C (hold for 1 minute) to 100 % B in 4 minutes, 100 % B for 5 minutes and reequilibrated with initial conditions for 3 minutes. An injection volume of 5 ⁇ l was used. Cone voltage was 20 V for positive ionization mode. Mass spectra were acquired by scanning from 100 to 900 in 0.8 seconds using an interscan delay of 0.08 seconds.
  • Method 2 In addition to the general procedure: Reversed phase HPLC was carried out on a Sunfire C18 column (3.5 ⁇ m, 4.6 x 100 mm) with an intial flow rate of 0.8 ml/min. Two mobile phases (mobile phase A: 25 % 7mM ammonium acetate + 50 % acetonitrile +25 % formic acid (2ml/l); mobile phase B: 100 % acetonitrile) were employed to run a gradient condition from 100 % A (hold for 1 minute) to 100 % B in 4 minutes, hold at 100 % B at a flow rate of 1.2 ml/min for 4 minutes and reequilibrated with initial conditions for 3 minutes). An injection volume of 10 ⁇ l was used. Cone voltage was 20 V for positive and negative ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.4 seconds using an interscan delay of 0.3 seconds.
  • the fluorescence was read in a computer-controlled fluorometer (Spectramax Gemini EM, Molecular Devices) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm.
  • the percentage growth inhibition achieved by the compounds was calculated according to standard methods and expressed as IC 90 ( ⁇ g/ml) which defines the 90 % inhibitory concentration for bacterial growth.
  • Untreated control samples with (column 1) and without (column 12) inoculum were included in each microtiter plate.
  • the same volume of broth medium without inoculum was added to column 12 in row A to H.
  • the cultures were incubated at 37°C for 48 hours in a humidified 5% CO 2 atmosphere (incubator with open air valve and continuous ventilation). At the end of incubation, two days after inoculation, the bacterial growth was quantitated fluorometrically. Therefore Alamar Blue (10x) was added to all wells in a volume of 20 ⁇ l and plates were incubated for another 2 hours at 50°C.
  • the fluorescence was read in a computer-controlled fluorometer (Cytofluor, Biosearch) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm (gain 30).
  • the percentage growth inhibition achieved by the compounds was calculated according to standard methods and expressed as IC 90 ( ⁇ g/ml) which defines the 90 % inhibitory concentration for bacterial growth.
  • the bacteria used in this study were grown overnight in flasks containing 100 ml Mueller-Hinton Broth (Becton Dickinson - cat. no. 275730) in sterile de-ionized water, with shaking, at 37°C. Stocks (0.5 ml/tube) were stored at -70 °C until use. Bacteria titrations were performed in microtiter plates to detect the TCID 50 , in which the TCID50 represents the dilution that gives rise to bacterial growth in 50 % of inoculated cultures. In general, an inoculum level of approximately 100 TCID 50 was used for susceptibility testing.
  • MIC 99 values (the minimal concentration for obtaining 99 % inhibition of bacterial growth) can be determined by performing the standard Agar dilution method according to NCCLS standards* wherein the media used includes Mueller-Hinton agar. * Clinical laboratory standard institute. 2005. Methods for dilution Antimicrobial susceptibility tests for bacteria that grows Aerobically: approved standard -sixth edition
  • Bactericidal or bacteriostatic activity of the compounds may be determined in a time kill assay using the broth microdilution method *.
  • a time kill assay on Staphylococcus aureus and methicillin resistant S. aureus (MRSA) the starting inoculum of S. aurues and MRSA is 10 6 CFU / ml in Muller Hinton broth.
  • the antibacterial compounds are used at the concentration of 0.1 to 10 times the MIC (i.e. IC 90 as determined in microtitre plate assay).
  • Wells receiving no antibacterial agent constitute the culture growth control.
  • the plates containing the microorganism and the test compounds are incubated at 37 °C.
  • assays are carried out by growing a culture of S. aureus (ATCC29213) stock in 100 ml Mueller Hinton flasks and incubate in a shaker-incubator for 24 hrs at 37 °C (300 rpm). Measure OD 405 nm and calculate the CFU/ml. Dilute the cultures to 1 x 10 6 CFU/ml (final concentration for ATP measurement: 1 x 10 5 CFU/100 ⁇ l per well) and add test compound at 0.1 to 10 times the MIC (i.e. IC 90 as determined in microtitre plate assay).
  • STA 29213 means Staphylococcus aureus (ATCC29213); SPN 6305 means Streptococcus pneumoniae (ATCC6305); EFA 29212 means Enterococcus faecalis (ATCC29212); SPY 8668 means Streptococcus pyogens (ATCC8668); PAE 27853 means Pseudomonas aeruginosa (ATCC27853); STA RMETH means methicilline resistant Staphylococcus aureus (MRSA) (a clinical isolate from the University of Antwerp); ECO 35218 means Escherichia coli (ATCC35218); MSM 607 means M. Smegmatis (ATCC607); ATCC means American type tissue culture;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
EP07847813A 2006-12-06 2007-12-04 Antibacterial quinoline derivatives Active EP2086941B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI200730286T SI2086941T1 (sl) 2006-12-06 2007-12-04 Antibakterijski kinolinski derivati
EP07847813A EP2086941B1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives
PL07847813T PL2086941T3 (pl) 2006-12-06 2007-12-04 Przeciwbakteryjne pochodne chinoliny
CY20101100708T CY1110706T1 (el) 2006-12-06 2010-07-28 Αντιβακτηριδιακα παραγωγα κινολινης

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06125521 2006-12-06
PCT/EP2007/063315 WO2008068269A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives
EP07847813A EP2086941B1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (2)

Publication Number Publication Date
EP2086941A1 EP2086941A1 (en) 2009-08-12
EP2086941B1 true EP2086941B1 (en) 2010-04-28

Family

ID=37944337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07847813A Active EP2086941B1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Country Status (30)

Country Link
US (1) US7998979B2 (ko)
EP (1) EP2086941B1 (ko)
JP (1) JP5356245B2 (ko)
KR (1) KR101490221B1 (ko)
CN (1) CN101541752B (ko)
AR (1) AR064150A1 (ko)
AT (1) ATE465994T1 (ko)
AU (1) AU2007328889B2 (ko)
BR (1) BRPI0720251B8 (ko)
CA (1) CA2668520C (ko)
CL (1) CL2007003516A1 (ko)
CY (1) CY1110706T1 (ko)
DE (1) DE602007006231D1 (ko)
DK (1) DK2086941T3 (ko)
ES (1) ES2344535T3 (ko)
HK (1) HK1137428A1 (ko)
HR (1) HRP20100384T1 (ko)
IL (1) IL199081A (ko)
JO (1) JO2685B1 (ko)
ME (1) ME01073B (ko)
MX (1) MX2009005980A (ko)
NO (1) NO341995B1 (ko)
NZ (1) NZ576673A (ko)
PL (1) PL2086941T3 (ko)
PT (1) PT2086941E (ko)
RS (1) RS51390B (ko)
RU (1) RU2446159C2 (ko)
SI (1) SI2086941T1 (ko)
TW (1) TWI412364B (ko)
WO (1) WO2008068269A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355050B (es) 2012-04-27 2018-04-02 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos.
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
CN104650054B (zh) * 2013-11-25 2019-09-13 重庆医药工业研究院有限责任公司 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
EP0936866A4 (en) 1996-10-28 2001-04-11 Dept Of The Army Us Government COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESIST INFECTIONS
CA2456173A1 (en) * 2001-07-31 2003-02-13 Wayne State University Quinoline derivatives and use thereof as antitumor agents
JP4484703B2 (ja) 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
EA011277B1 (ru) * 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
ATE392423T1 (de) 2004-01-23 2008-05-15 Janssen Pharmaceutica Nv Substituierte chinoline und deren verwendung als inhibitoren von mycobakterien
WO2005075428A1 (en) * 2004-01-29 2005-08-18 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
KR20130024969A (ko) * 2004-05-28 2013-03-08 얀센 파마슈티카 엔.브이. 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린 유도체의 용도
CN101065397B (zh) 2004-09-28 2015-10-21 詹森药业有限公司 一种细菌atp合酶的结合结构域

Also Published As

Publication number Publication date
NZ576673A (en) 2011-09-30
CN101541752B (zh) 2013-07-17
PL2086941T3 (pl) 2010-10-29
JP5356245B2 (ja) 2013-12-04
KR101490221B1 (ko) 2015-02-05
ES2344535T3 (es) 2010-08-30
HRP20100384T1 (hr) 2010-08-31
DK2086941T3 (da) 2010-08-09
BRPI0720251B8 (pt) 2021-05-25
NO341995B1 (no) 2018-03-12
IL199081A (en) 2013-08-29
ATE465994T1 (de) 2010-05-15
NO20092540L (no) 2009-09-07
PT2086941E (pt) 2010-07-14
EP2086941A1 (en) 2009-08-12
DE602007006231D1 (de) 2010-06-10
AR064150A1 (es) 2009-03-18
AU2007328889B2 (en) 2012-12-06
KR20090087071A (ko) 2009-08-14
AU2007328889A1 (en) 2008-06-12
CN101541752A (zh) 2009-09-23
TW200845987A (en) 2008-12-01
CY1110706T1 (el) 2015-06-10
US20100063061A1 (en) 2010-03-11
MX2009005980A (es) 2009-06-16
JO2685B1 (en) 2013-03-03
US7998979B2 (en) 2011-08-16
TWI412364B (zh) 2013-10-21
HK1137428A1 (en) 2010-07-30
RS51390B (en) 2011-02-28
SI2086941T1 (sl) 2010-08-31
CA2668520C (en) 2016-01-26
RU2009125525A (ru) 2011-01-20
WO2008068269A1 (en) 2008-06-12
BRPI0720251B1 (pt) 2020-10-06
BRPI0720251A2 (pt) 2014-01-07
ME01073B (me) 2012-10-20
CL2007003516A1 (es) 2008-07-11
CA2668520A1 (en) 2008-06-12
JP2010511670A (ja) 2010-04-15
RU2446159C2 (ru) 2012-03-27

Similar Documents

Publication Publication Date Title
EP2099758B1 (en) Antibacterial quinoline derivatives
EP2099762B1 (en) Antibacterial quinoline derivatives
EP2099759B1 (en) Antibacterial quinoline derivatives
EP2086941B1 (en) Antibacterial quinoline derivatives
EP2099760B1 (en) Antibacterial quinoline derivatives
EP2099761B1 (en) Antibacterial quinoline derivatives
AU2007328888B2 (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602007006231

Country of ref document: DE

Date of ref document: 20100610

Kind code of ref document: P

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20100384

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20100707

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2344535

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20100384

Country of ref document: HR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20100401797

Country of ref document: GR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 7540

Country of ref document: SK

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E008735

Country of ref document: HU

26N No opposition filed

Effective date: 20110131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101204

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20100384

Country of ref document: HR

Payment date: 20181109

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20100384

Country of ref document: HR

Payment date: 20191111

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20100384

Country of ref document: HR

Payment date: 20201116

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20100384

Country of ref document: HR

Payment date: 20211203

Year of fee payment: 15

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20100384

Country of ref document: HR

Payment date: 20221201

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20221202

Year of fee payment: 16

Ref country code: SK

Payment date: 20221115

Year of fee payment: 16

Ref country code: SE

Payment date: 20221110

Year of fee payment: 16

Ref country code: RO

Payment date: 20221122

Year of fee payment: 16

Ref country code: PT

Payment date: 20221205

Year of fee payment: 16

Ref country code: NL

Payment date: 20221114

Year of fee payment: 16

Ref country code: MC

Payment date: 20221128

Year of fee payment: 16

Ref country code: LV

Payment date: 20221103

Year of fee payment: 16

Ref country code: LU

Payment date: 20221129

Year of fee payment: 16

Ref country code: LT

Payment date: 20221124

Year of fee payment: 16

Ref country code: IT

Payment date: 20221111

Year of fee payment: 16

Ref country code: IE

Payment date: 20221109

Year of fee payment: 16

Ref country code: GB

Payment date: 20221103

Year of fee payment: 16

Ref country code: FR

Payment date: 20221110

Year of fee payment: 16

Ref country code: FI

Payment date: 20221209

Year of fee payment: 16

Ref country code: EE

Payment date: 20221103

Year of fee payment: 16

Ref country code: DK

Payment date: 20221213

Year of fee payment: 16

Ref country code: DE

Payment date: 20220622

Year of fee payment: 16

Ref country code: CZ

Payment date: 20221116

Year of fee payment: 16

Ref country code: BG

Payment date: 20221116

Year of fee payment: 16

Ref country code: AT

Payment date: 20221125

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20221118

Year of fee payment: 16

Ref country code: PL

Payment date: 20221115

Year of fee payment: 16

Ref country code: IS

Payment date: 20221109

Year of fee payment: 16

Ref country code: HU

Payment date: 20221126

Year of fee payment: 16

Ref country code: GR

Payment date: 20221114

Year of fee payment: 16

Ref country code: BE

Payment date: 20221118

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20221223

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230113

Year of fee payment: 16

Ref country code: CH

Payment date: 20230101

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20221202

Year of fee payment: 16

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E004535

Country of ref document: EE

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20100384

Country of ref document: HR

Effective date: 20231204

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20231204

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007006231

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 7540

Country of ref document: SK

Effective date: 20231204

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231205

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240604

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20240101

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E004535

Country of ref document: EE

Effective date: 20231231

Ref country code: AT

Ref legal event code: MM01

Ref document number: 465994

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240102

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231204

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240604

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240102

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240101

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20240813

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240702

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231